We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Realm Thera. | LSE:RLM | London | Ordinary Share | GB00B3XBCR18 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 10.00 | 13.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMRLM
RNS Number : 2816H
Realm Therapeutics PLC
06 June 2017
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Result of 2017 Annual General Meeting
6 June 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.
Enquiries:
+44 (0) 20 3727 Realm Therapeutics plc 1000 Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer +44 (0) 20 3727 FTI Consulting 1000 Simon Conway / Mo Noonan N+1 Singer (Nominated Adviser & +44 (0) 20 7496 Broker) 3000 Aubrey Powell / Lauren Kettle
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUNRRRBSANRAR
(END) Dow Jones Newswires
June 06, 2017 06:05 ET (10:05 GMT)
1 Year Realm Thera. Chart |
1 Month Realm Thera. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions